Impact of neoadjuvant chemotherapy on survival prognosis and pathological downstaging in patients presenting with high-risk upper tract urothelial carcinoma

A protocol for systematic review and meta analysis

Kun Li², Wenjie Xie³, Liang Gao⁴, Gaomin Huang⁴, Jiaming Zhou⁴, Baoyu Mei⁵, Jie Chen, MD, PhD⁵,*

Abstract

Purpose: Controversy remains with using neoadjuvant chemotherapy (NAC) in patients with upper tract urothelial carcinoma (UTUC). Thus, we conducted a systematic review and meta-analysis of the peer-reviewed literature to assess the role of NAC in high-risk UTUC patients.

Methods: PubMed, EMBASE, and the Cochrane Library were the main sources of relevant studies. The search terms included: “Upper urothelial carcinoma”; “UTUC”; “Urinary tract cancer”; and “Transitional cell carcinoma” combined with “Neoadjuvant chemotherapy” and “adjuvant chemotherapy”. We studied the relationship of UTUC and NAC. Overall survival, recurrent-free survival, cancer-specific survival and pathological response rate in patients treated with/without NAC before radical surgery were evaluated.

Results: Five trials were selected, and included 532 participants. Each of the included studies was retrospective. The combined analysis showed that when compared to controls, the pooled hazard ratios of overall survival, recurrence-free survival and cancer-specific survival were 0.47 (95% confidence interval [CI], 0.34–0.64; P < .00001); 0.50 (95% CI, 0.37–0.66; P < .00001); and 0.37 (95% CI, 0.25–0.54; P < .00001), respectively. It indicates the beneficial effects of NAC for the prognosis of survival in UTUC. Additionally, NAC was significantly associated with T-stage down-grading (T3/4 to ≤T2; OR=7.58 [4.66, 12.33]; P < .0001) and pathological lymph node status (N+ to N0; OR=6.24 [2.57,15.15]; P < .00001).

Conclusions: NAC treatment before radical nephroureterectomy significantly improves survival prognosis in patients with high-risk upper tract urothelial carcinoma. However, considerable prospective and randomized studies are needed to confirm this perspective.

Abbreviations: CI = confidence interval, CR = complete response, CSS = cancer-specific survival, HR = hazard ratio, NAC = neoadjuvant chemotherapy, NOS = Newcastle-Ottawa scale, OR = odds ratio, OS = overall survival, RFS = recurrence-free survival, RNU = radical nephroureterectomy, UCB = urothelial carcinoma of bladder, UTUC = upper tract urothelial carcinoma.

Keywords: meta-analysis, neoadjuvant chemotherapy, nephroureterectomy, upper tract urothelial carcinoma

1. Introduction

Upper tract urothelial carcinoma (UTUC) refers to any particular type of malignancy that arise from the urothelial lining of the urinary tract, from the calyceal system to the distal ureter. UTUC is a relatively uncommon entity, accounting for 5% to 10% of all urothelial tumors.¹,² Several studies have suggested that patient prognosis after radical surgery for high-risk UTUC has not improved over the 18-year period that this condition has been
assessed.\textsuperscript{[3]} Adjuvant chemotherapy has been regarded as an acceptable therapeutic choice; however, deterioration of renal function after radical nephroureterectomy (RNU) can lead to a decreased eligibility to be considered for systemic chemotherapy.\textsuperscript{[4,5]} The evidence strongly suggests an urgent need to alter treatment options. A multimodal means of managing high-risk UTUC by incorporating neoadjuvant chemotherapy (NAC) and RNU with excision of the ipsilateral bladder cuff might improve patient outcomes.\textsuperscript{[6]} Several studies on bladder cancer have indicated that NAC has significantly improved outcomes in invasive bladder cancer\textsuperscript{[7]} although the benefit of NAC in high-risk UTUC remains controversial and somewhat disputed. Although some retrospective studies have assessed the potential benefit of NAC for UTUC\textsuperscript{[6,8–11]} there are few prospective cohort studies that have actually evaluated the benefits.\textsuperscript{[14,15]} Chemotherapy regimens for patients with UTUC are similar to those of urothelial carcinoma of bladder (UCB) based on the European Association of Urology (EAU) guidelines. In addition, cisplatin-based NAC is considered to be the most reasonable standard of therapy in patients with UCB or locally advanced UTUC.\textsuperscript{[13]} Matin et al\textsuperscript{[14]} reported their experience with 43 patients that presented with high-risk UTUC and received a cisplatin-based NAC. These patients demonstrated a 53.5% overall response rate and a 14% pathologic complete response (CR) rate. A recent retrospective study included 61 patients with high-grade UTUC. Of these 25 patients who received NAC, 80% had any reduction in tumor size observed by imaging. In postoperative pathology, only 20% of patients in the NAC group have ≥pT2 disease, compared with 64% of patients undergoing only RNU surgery.\textsuperscript{[13]} However, owing to the limited number of subjects that were included in these studies, it was impossible to appraise the benefits of NAC in patients considered for this mode of therapy. In the current work, we conducted a meta-analysis to assess the role of NAC in patients presenting with high-risk UTUC.

2. Materials and methods

The PRISMA guidelines were used in the design of this study, which was conducted in accordance with the ethical guidelines of the Declaration of Helsinki.

2.1. Literature search strategy

PubMed, EMBASE, and the Cochrane Library were the main sources of relevant primary peer-reviewed studies for his study. Two independent reviewers searched records from January 1998 through January 2019. All studies evaluated the role of NAC in the setting of UTUC. Literature searches were limited to the English language. Nevertheless, we referred to the reference citations of the papers to identify additional eligible articles.

3. Study selection

The criteria of the study included the following:

(1) The study evaluated the role of NAC for UTUC;
(2) All patients were diagnosed with primary high-risk UTUC;
(3) All patients were not treated with chemotherapy after surgery;
(4) Outcomes were OS, cancer-specific survival (CSS), recurrence-free survival (RFS) and the pathological response rate.

Both prospective cohort studies and retrospective trials were included in our study. Data from summaries, reviews, editorials, animal studies, case reports, and letters were excluded. Lower urothelial carcinoma and those studies with participants that contained incomplete data were also excluded.

3.1. Data extraction and quality assessment

The statistics below were collected from individual studies by 2 reviewers independently: details on study design, age of patients, the number of test and control groups, and treatment regimen, median follow-up period, T stage, and outcomes measured (ie, pathological response rate, OS, CSS, and RFS) were interrogated. According to the suggestions put forward by the Cochrane Non-Randomized Studies Methods Working Group, the Newcastle–Ottawa Scale (NOS) was applied to quality assess the included studies in this meta-analysis. This scale allocates up to nine stars according to an assessment of selection, comparability, and exposure. Studies that received six or more stars were considered to be high quality.

3.2. Statistical analysis

Meta-analyses were performed in Review Manager v.5.3 software (RevMan, The Cochrane Collaboration). The hazard ratio (HR, for OS; RFS and CSS) or the odds ratio (OR, for T-stage down-grading and the incidence of declining lymph node-positive disease) with its corresponding 95% confidence interval (CI) were used to assess the pooled influence. The $I^2$ statistic and Cochran $Q$ statistic was used to assess the heterogeneity across the included studies. $I^2 > 50\%$ or the $Q$ statistic $<.05$ was considered to be significantly heterogeneous. If the heterogeneity was obvious, we would use a randomized effects model; otherwise, a fixed effects model was used. Sensitivity analyses were conducted to evaluate the influence of individual studies on the overall estimates by omitting 1 study at each turn. According to the Cochrane manual, we did not use funnel plots to assess publication bias because fewer than 10 studies were included in the current study.

4. Search results

The literature screening flow chart is shown in Figure 1. Overall, 1084 studies were identified from the databases and relevant references, of which 902 were reserved after removing duplicates. Two reviewers assessed the selected 902 relevant articles on the basis of titles and abstracts, and 872 were excluded from this analysis. Next, after evaluating the full-text articles, 5 were identified as eligible for this meta-analysis, including a total of 532 participants. There were 222 patients who received NAC before surgery, and 310 patients experienced RNU alone. The detailed information of each included study is presented in Tables 1 and 2. According to the NOS criteria, the overall quality of the included study was at low risk of bias in the NOS scores $\geq 6$. The results are presented in Table 3.

5. Main findings

5.1. Survival index

Five studies were included in the OS subgroup.\textsuperscript{[8–11,16]} Statistical analysis showed that the pooled HR was 0.47 (95\% CI: 0.34–0.64; $P < .00001$), which indicated that NAC plus RNU was associated with a significant OS improvement as compared
with those that underwent RNU alone (Fig. 2). There was no statistically significant heterogeneity among any of the studies according to the Cochran Q statistical analysis ($P = .41$) and $I^2 = 0\%$.

5.2. RFS

RFS results were reported in 3 studies.$^{[9,11]}$ In 1 study, however, intravesical and visceral RFS were done separately and respectively.$^{[11]}$ The meta-analysis revealed that pooled HR was 0.50 (95% CI:0.37–0.66; $P < .00001$), which indicated that NAC plus RNU was also associated with a significant RFS improvement as compared those that received RNU alone (Fig. 3). Analysis showed no statistically significant heterogeneity among studies according to Cochran Q statistics ($P = .64$) and $I^2 = 0\%$.

5.3. CSS

CSS were provided in 4 studies.$^{[8–11]}$ The pooled HR was 0.37 (95% CI:0.25–0.54; $P < .00001$), which indicated that NAC plus RNU was also associated with significant CSS improvement as compared with those that underwent RNU alone (Fig. 4). There was no statistically significant heterogeneity among studies on the basis of Cochran Q statistics ($P = .56$) and $I^2 = 0\%$.

5.4. Pathological downgrading

5.4.1. T stage. The possible association between NAC and T stage down-grading was investigated in 4 studies,$^{[9–11,16]}$ which collectively showed no statistically significant heterogeneity among studies on the basis of Cochran Q statistics ($P = .94$) and $I^2 = 0\%$. The pooled OR of having T stage down-grading was 7.58 (95% CI:4.66–12.33; $P < .00001$; Fig. 5). These results inform us that the NAC group had a 6.58-fold higher possibility of having T stage down-grading (T3/4 to ≤T2) as compared with the control group.

5.5. Pathologic lymph node status

The role of NAC before RNU on the rate of lymph node-positive disease was reported in 4 studies.$^{[9–11,16]}$ There was no statistically significant heterogeneity in these studies ($P = .63$, $I^2 = 0\%$). The pooled OR of the declined incidence of lymph node-positive disease was 6.24 (95% CI:2.57–15.15; $P < .0001$; Fig. 6). The results illustrate that the NAC group had a 5.24-fold
higher possibility of having a declining incidence of lymph node-positive disease as compared to the control group.

5.6. Sensitivity analyses

We performed sensitivity analyses by omitting 1 study at a time, generating pooled estimates and comparing the pooled with the original estimates. These findings demonstrated that our results were trustworthy.

6. Discussion

RNU with bladder cuff excision is considered a standard treatment for high-risk UTUC, regardless of the location of the tumor. However, Margulis et al. [17] found that patients undergoing RNU surgery alone could not bring an oncological benefit to those patients with high-risk UTUC. Increasing evidence shows that UTUC is a distinct disease entity from UCB on the basis of both phenotypic and genotypic (genetic and epigenetic) differences. In addition, more than 60% of UTUCs,

| First author | NAC cases (n) | Age (yr) | cN+ | pN+ | cT3–4 | pT3–4 | Median follow-up time (mo) |
|--------------|--------------|---------|-----|-----|-------|-------|---------------------------|
| Kubota (11)  | 101          | 70±9.5  | 19  | 11  | 100   | 36    | 26                        |
| Hosogoe (10) | 51           | 70±9.6  | 15  | 7   | 49    | 17    | 24                        |
| Kobayashi (9) | 31          | 67±15   | 24  | 14  | 22    | 18    | 33                        |
| Porten (8)   | 15           | 70 (32–89) |  –  |  –  |  –    |  –    | –                         |
| Kitamura (16) | 24          | 65      | 15  | 4   | 11    | 7     | –                         |

Table 3

Quality assessment of studies included in meta-analysis.

| First author | Selection | Selection | Selection | Selection | Comparability | Exposure | Exposure | Exposure | Scores |
|--------------|-----------|-----------|-----------|-----------|---------------|----------|----------|----------|--------|
| Kubota (11)  |  *        |  *        |  **       |  **       |  *            |  *       |  *       |  *       | 6      |
| Hosogoe (10) |  *        |  *        |  **       |  **       |  *            |  *       |  *       |  *       | 6      |
| Kobayashi (9) |  *       |  *        |  **       |  **       |  *            |  *       |  *       |  *       | 6      |
| Porten (8)   |  *        |  *        |  **       |  **       |  *            |  *       |  *       |  *       | 6      |
| Kitamura (16) |  *      |  *        |  **       |  **       |  *            |  *       |  *       |  *       | 6      |

Figure 2. Forest plots of 5-yr overall survival rates.
and only 15% to 25% of UCB present with invasion at the time of diagnosis.[18] There is usually a poor prognosis if UTUCs have invaded the muscle wall. The 5 year specific survival rate is < 50% for pT2/pT3 and < 10% for pT4.[19,20] Some scholars have proposed perioperative chemotherapy due to the high recurrence rate of UTUC. Similar to UCB, several platinum-based chemotherapeutic regimens have been put forward for UTUC. Some studies report that many patients are unable to receive chemotherapy after RNU due to decreased renal function[21]; however, NAC capitalizes on the patient’s maximal renal reserve.

**Figure 3.** Forest plots of 5-yr recurrence-free survival rates.

**Figure 4.** Forest plots of 5-yr cancer-specific survival rates.

**Figure 5.** Forest plots of NAC effects on T-stage down-grading (T3/4 to ≤T2).

**Figure 6.** Forest plots of NAC effects on the pathologic lymph node status (N+ to N0).
to deliver optimal doses of chemotherapy. Unfortunately, these guidelines were intended to align with UTIC treatment with NAC, and primarily based on UCB treatment guidelines.\[^{22}\]

Some retrospective studies have explored the role of NAC in patients with high-risk UTIC. Igawa et al reported a 13% pathological CR rate and a 40% partial response rate when using cisplatin-based NAC in locally advanced UTIC.\[^{23}\]\[^{24}\] Matin et al found that when using NAC before radical surgery, this resulted in an obvious rate of downstaging and a 14% pathological CR rate.\[^{14}\]\[^{15}\]\[^{16}\] After comprehensively searching for the relationship between NAC and survival prognosis in UTUC patients, 2 meta-analyses showed significant improvements in OS and CSS in the NAC group as compared to controls.\[^{24,25}\]\[^{26}\] A recent study from China has also confirmed the survival benefits of NAC in high-grade UTUC patients. Patients who received NAC before surgery had significantly improved overall and disease-free survival.\[^{26}\]\[^{27}\]

In addition, 2 prospective studies were identified that reported using NAC in UTIC patients. Both studies were phase 2 clinical trials that were conducted that the MD Anderson Cancer Center, Texas, USA. A study consisted of 65 subjects, among which only 5 were high-grade UTUC. These 5 patients received NAC before radical surgery, and 3 of these patients (60%) showed a pathologic down-staging to ≤ pT1N0 disease, which demonstrated that NAC was effective in UTIC patients.\[^{12}\]\[^{13}\]\[^{14}\][^21] Another study reported that NAC led to a pathologic down-staging in twelve (75%) of sixteen patients with upper tract cancer.\[^{17}\]\[^{18}\] However, due to an insufficient number of subjects in these studies, the conclusion with regard the clinical benefits of NAC for UTIC were unconvincing.

The present study was based on a retrospective case-control study and explored the effect of NAC on the risk of OS, RFS, CSS and pathological down-grading when treating UTUC. The pooled HR for 5 year OS, RFS, and CSS were 0.47 (95% CI, 0.34–0.64), 0.50 (95% CI, 0.37–0.66), and 0.37 (95% CI, 0.25–0.54), respectively. These findings from the meta-analysis indicated that when compared with control subjects, NAC was significantly beneficial on OS, RFS, and CSS. With regard the pathological changes, the date showed that the NAC group had a 6.58-fold higher probability of having T stage down-grading (T3/4 to ≤T2) and had a 5.24-fold higher probability of demonstrating a declining incidence of lymph node-positive disease as compared the control group. These findings have significant reference value on treating high-risk UTIC.

### 6.1. Limitations

The main limitation of this systematic review was the lack of included RCTs for evaluation, and a possibility of some selection bias that might have affected our results. Further, the number of samples included in this study was small, and the availability of adequate data is challenging when considering the acquisition of meaningful results. The difference in the skills and technical knowledge of practicing surgeons might also markedly impact the outcomes. Although some studies had confirmed the survival benefit of NAC, it remains controversial when considering the use of NAC before RNU. Therefore, it is imperative to carry out large-scale, well-designed randomized controlled trials in this context.

### 7. Conclusions

NAC treatment before RNU can significantly improve survival prognosis and increase the pathological down-grading rate in patients with high-risk UTUC. However, we still need many other prospective randomized studies to permit a confirmation of this perspective.

### Author contributions

Study conception: J.C, K.L.
Study design: J.C, L.G., and L.G.
Acquisition of data: K.L., G.M.H., and B.Y.M.
Analysis and Interpretation of data: K.L., J.C, L.G., G.M.H., J.M., Z., and W.J.X.

Drafting of the Manuscript: K.L., J.C., and W.J.X.

All authors have contributed to the critical revision and approval of the final manuscript.

### References

[1] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016;66:6–25.
[2] Soria F, Shariat SF, Lerner SP, et al. Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC). World J Urol 2017;35:249–270.
[3] Brown GA, Busby JE, Wood CG, et al. Neoplastic tumor cells for treating upper urinary tract transitional cell carcinoma: time to change the treatment paradigm? BJU Int 2006;98:1176–1180.
[4] Loew JJ, Martin-Doyle W, Fay AP, et al. A systematic review and meta-analysis of adjuvant and neoadjuvant chemotherapy for upper tract urothelial carcinoma. Eur Urol 2014;66:529–541.
[5] Xylinas E, Rink M, Margulis V, et al. Impact of renal function on eligibility for chemotherapy and survival in patients who have undergone radical nephro-ureterectomy. BJU Int 2013;112:435–441.
[6] Almassi N, Gao T, Lee B, et al. Impact of neoadjuvant chemotherapy on pathologic response in patients with upper tract urothelial carcinoma undergoing extirpative surgery. Clin Genitourin Cancer 2018;16:e1237–e1242.
[7] Griffiths G, Hall R, Sylvester R, et al. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol 2011;29:2171–2177.
[8] Porten S, Siefker-Radtke AO, Xiao L, et al. Neoadjuvant chemotherapy improves survival of patients with upper tract urothelial carcinoma. Cancer 2014;120:1794–15.
[9] Kobayashi K, Saito T, Kitamura Y, et al. Effect of preoperative chemotherapy on survival of patients with upper urinary tract urothelial carcinoma clinically involving regional lymph nodes. Int J Urol 2016;23:133–138.
[10] Hosogoe S, Hatakeyama S, Kusaka A, et al. Platinum-based neoadjuvant chemotherapy improves oncological outcomes in patients with locally advanced upper tract urothelial carcinoma. Eur Urol Focus 2018;4:946–953.
[11] Kubota Y, Hatakeyama S, Tanaka T, et al. Oncological outcomes of neoadjuvant chemotherapy in patients with locally advanced upper tract urothelial carcinoma: a multicenter study. Oncotarget 2017;8:101490–101500.
[12] Siefker-Radtke AO, Dinney CP, Shen Y, et al. A phase 2 clinical trial of sequential neoadjuvant chemotherapy with ifosfamide, doxorubicin, and gemcitabine followed by cisplatin, gemcitabine, and ifosfamide in locally advanced urothelial cancer: final results. Cancer 2013;119:540–7.
[13] O’Donnell PH, Stadler WM. The role of chemotherapy in upper tract urothelial carcinoma. Adv Urol 2009;2009:419028.
[14] Matin SF, Margulis V, Kamar A, et al. Incidence of downstaging and complete remission after neoadjuvant chemotherapy for high-risk upper tract transitional cell carcinoma. Cancer 2010;116:3127–34.
[15] Meng X, Chao B, Vijay V, et al. High response rates to neoadjuvant chemotherapy in high-grade upper tract urothelial carcinoma. Urology 2019;129:146–52.
[16] Kitamura H, Igarashi M, Tanaka T, et al. A role for preoperative systemic chemotherapy in node-positive upper tract urothelial carcinoma treated with radical nephroureterectomy. Jpn J Clin Oncol 2012;42:1192–4.
[17] Margulis V, Shariat SF, Matin SF, et al. Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration. Cancer 2009;113:1224–33.

---

**Medicine**

Li et al. Medicine (2020) 99:18
[18] Leow JJ, Chong KT, Chang SL, et al. Upper tract urothelial carcinoma: a different disease entity in terms of management. ESMO Open 2017;1:e000126–130.
[19] Rouprêt M, Babjuk M, Compérat E, et al. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2017 Update. Eur Urol 2018;73:111–22.
[20] Lughezzani G, Burger M, Margulis V, et al. Prognostic factors in upper urinary tract urothelial carcinomas: a comprehensive review of the current literature. Eur Urol 2012;62:100–14.
[21] Lane BR, Smith AK, Larson BT, et al. Chronic kidney disease after nephroureterectomy for upper tract urothelial carcinoma and implications for the administration of perioperative chemotherapy. Cancer 2010;116:2967–73.
[22] Vale CL. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data: advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol 2005;48:202–6.
[23] Igawa M, Urakami S, Shiina H, et al. Neoadjuvant chemotherapy for locally advanced urothelial cancer of the upper urinary tract. Urol Int 1995;55:74–7.
[24] Gregg RW, Vera-Badillo FE, Booth CM, et al. Perioperative chemotherapy for urothelial carcinoma of the upper urinary tract: a systematic review and meta-analysis. Crit Rev Oncol Hematol 2018;128:58–64.
[25] Yang X, Li P, Deng X, et al. Perioperative treatments for resected upper tract urothelial carcinoma: a network meta-analysis. Oncotarget 2017;8:3568–80.
[26] Chen L, Ou Z, Wang R, et al. Neoadjuvant chemotherapy benefits survival in high-grade upper tract urothelial carcinoma: a propensity score-based analysis. Ann Surg Oncol 2020;27:1297–303.
[27] Siefker-Radtke AO, Kamat AM, Corn PG, et al. Neoadjuvant chemotherapy with DD-MVAC and bevacizumab in high-risk urothelial cancer: results from a phase II trial at the M. D Anderson Cancer Center 2012;30:261.